Clinical efficacy of low‐dose Perampanel correlates with neurophysiological changes in familial adult myoclonus epilepsy 2
Abstract Familial adult myoclonus epilepsy (FAME) management relies on antiseizure medications (ASMs), which inadequately address myoclonus and cortical tremor. This study evaluates Perampanel (PER), an AMPA‐receptor antagonist, for treating FAME symptoms. Fifteen FAME2 patients participated in an o...
Saved in:
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-02-01
|
Series: | Epilepsia Open |
Subjects: | |
Online Access: | https://doi.org/10.1002/epi4.13100 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!